Form 4: Corbus Pharmaceuticals Director Alan Holmer Receives Significant Equity Grant

Corbus Pharmaceuticals Holdings, Inc. Director Alan F. Holmer was granted 4,800 restricted stock units and 16,000 stock options as part of the company's 2024 Equity Compensation Plan.

Summary

• Alan F. Holmer, a Director of Corbus Pharmaceuticals Holdings, Inc. (CRBP), reported new equity grants on May 30, 2025.
• He was granted 4,800 restricted stock units (RSUs) with a par value of $0.0001 per share, which will vest 100% on the one-year anniversary of the grant date (May 30, 2026).
• Additionally, Mr. Holmer received 16,000 stock options with an exercise price of $7.42 per share.
• These stock options will also vest 100% on the one-year anniversary of the grant date (May 30, 2026) and have an expiration date of May 30, 2035.
• The equity awards were made in accordance with the terms of the issuer's 2024 Equity Compensation Plan.
• Following these transactions, Mr. Holmer beneficially owns 10,629 shares of common stock (including the 4,800 unvested RSUs) and 16,000 stock options.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates standard corporate governance practices for director compensation, aligning interests with shareholders. It's a routine transaction and not indicative of significant operational or financial news.

Positives

• The equity grants align the director's interests with those of the shareholders, as his compensation is tied to the company's future stock performance.
• The grants are part of a pre-approved 2024 Equity Compensation Plan, indicating a structured approach to executive and director incentives.

Negatives

• The RSUs and stock options are unvested for one year, meaning the director does not immediately gain full ownership or the ability to exercise the options.

Risks

• The value of the granted RSUs and stock options is subject to the future performance and volatility of Corbus Pharmaceuticals' common stock.
• There is a risk that the stock price may not exceed the option exercise price of $7.42, rendering the options less valuable or worthless at expiration.

Future Outlook

The future outlook for the director's holdings includes the vesting of 4,800 restricted stock units and 16,000 stock options on May 30, 2026, which will increase his direct beneficial ownership of common stock and exercisable options.

Management Comments

• The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan.
• The RSUs will vest 100% on the one-year anniversary from the date of grant.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize directors and executives, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is a common practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The one-year vesting period for these grants is a typical structure for annual equity awards to directors, aiming to ensure continued engagement and alignment over a reasonable timeframe.
• The exercise price of $7.42 for the options is likely based on the market price of CRBP common stock on the grant date, which is standard for incentive stock options.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees: While this specific filing is for a director, the use of an equity compensation plan suggests a broader framework for incentivizing key personnel, which can positively impact employee retention and motivation.

Next Steps

• The restricted stock units and stock options are scheduled to vest 100% on May 30, 2026.

Key Dates

Keywords

Corbus Pharmaceuticals, CRBP, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership